Moderately to severely active Crohn's disease (CD) in adults who have had an inadequate response or intolerance to one or more TNF blockers.

Moderately to severely active ulcerative colitis (UC) in adults who have had an inadequate response or intolerance to one or more TNF blockers.

Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or other immunosuppressants.

Refractory, moderate to severe atopic dermatitis (AD) in adults and pediatric patients 12 years of age and older whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.

Limitations of Use: RINVOQ is not recommended for use in combination with other Janus kinase (JAK) inhibitors, biologic disease-modifying antirheumatic drugs (bDMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine.

Active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation in adults who have had an inadequate response or intolerance to TNF blocker therapy.

Active ankylosing spondylitis (AS) in adults who have had an inadequate response or intolerance to one or more TNF blockers.Active psoriatic arthritis (PsA) in adults who have had an inadequate response or intolerance to one or more TNF blockers.Moderately to severely active rheumatoid arthritis (RA) in adults who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.RINVOQ is indicated for the treatment of: IMPORTANT SAFETY INFORMATION & INDICATIONS 1 INDICATIONS 1 No claims for payment may be submitted to any third party for product dispensed by program. This is not health insurance and program does not guarantee insurance coverage. Offer subject to change or discontinuance without notice.

Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Program provides for RINVOQ at no charge to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier, and is not contingent on purchase requirements of any kind. Continued eligibility for the program requires the submission of an appeal of the coverage denial every 180 days. Patients must have a valid prescription for RINVOQ® (upadacitinib) for an FDA approved indication and a denial of insurance coverage based on a prior authorization request on file along with a confirmation of appeal. ‡Eligibility criteria: Available to patients aged 63 or younger with commercial insurance coverage.

Humira copay card program